HC Wainwright Estimates argenex’s Q3 Earnings (NASDAQ:ARGX)

argenex SE (NASDAQ:ARGX) – Research analysts at HC Wainwright raised their Q3 2026 earnings estimates for argenex in a report released on Friday, July 24th. HC Wainwright analyst D. Tsao now anticipates that the company will post earnings of $6.51 per share for the quarter, up from their previous forecast of $6.48. HC Wainwright has a “Buy” rating and a $940.00 price target on the stock. The consensus estimate for argenex’s current full-year earnings is $26.95 per share. HC Wainwright also issued estimates for argenex’s Q1 2027 earnings at $7.57 EPS, Q2 2027 earnings at $8.41 EPS, Q3 2027 earnings at $8.86 EPS and Q4 2027 earnings at $9.53 EPS.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a net margin of 32.19% and a return on equity of 43.59%. The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion.

ARGX has been the subject of a number of other research reports. Wells Fargo & Company lifted their price objective on argenex from $1,260.00 to $1,291.00 and gave the company an “overweight” rating in a research note on Monday, June 1st. Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a report on Saturday. Bank of America lifted their price target on argenex from $1,016.00 to $1,088.00 and gave the stock a “buy” rating in a research report on Thursday, July 2nd. Weiss Ratings cut shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Finally, Glj Research upgraded shares of argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $1,054.11.

argenex Stock Down 3.2%

ARGX stock opened at $888.82 on Monday. argenex has a twelve month low of $590.78 and a twelve month high of $953.58. The firm has a market cap of $55.60 billion, a PE ratio of 34.13, a price-to-earnings-growth ratio of 1.21 and a beta of 0.45. The business has a 50 day moving average of $870.53 and a 200 day moving average of $815.82.

Institutional Investors Weigh In On argenex

Large investors have recently bought and sold shares of the business. Sound Income Strategies LLC purchased a new position in argenex in the 4th quarter worth about $28,000. Whipplewood Advisors LLC bought a new stake in shares of argenex in the first quarter worth approximately $28,000. Eastern Bank bought a new stake in shares of argenex in the second quarter worth approximately $32,000. Sunbelt Securities Inc. purchased a new position in shares of argenex during the third quarter valued at approximately $36,000. Finally, Axiom Investment Management LLC purchased a new position in shares of argenex during the first quarter valued at approximately $50,000. 60.32% of the stock is currently owned by institutional investors.

argenex News Roundup

Here are the key news stories impacting argenex this week:

• Positive Sentiment: argenx agreed to acquire Forte Biosciences (NASDAQ: FBRX) for $77 per share in cash, representing an equity value of approximately $2.2 billion and a 41% premium to Forte’s prior closing price. The transaction gives argenx full ownership of FB102, an experimental autoimmune therapy. argenx acquisition announcement
• Positive Sentiment: FB102’s Phase 1b data in vitiligo and celiac disease reportedly support CD122 biology and a potential “pipeline-in-a-product” opportunity targeting pathogenic T-cell and NK-cell activity in diseases with significant unmet need. The acquisition broadens argenx’s immunology pipeline beyond its existing portfolio. argenx Forte acquisition details
• Positive Sentiment: Analyst sentiment remains supportive in parts of the market: Robert W. Baird raised its price target to $932, while HC Wainwright increased its earnings estimates. A separate Oppenheimer report had previously lifted its target to $1,037.
• Neutral Sentiment: Baird maintained a “neutral” rating despite the higher target, implying that the acquisition’s long-term value is not yet fully reflected in near-term expectations. Baird price target report
• Negative Sentiment: The all-cash $2.2 billion transaction represents a substantial capital commitment for a clinical-stage asset. Investors may be concerned about integration costs, future development spending and the risk that FB102’s early-stage results do not translate into successful late-stage trials or commercialization. One analysis consequently rated the stock “Hold.” Forte and argenx investment analysis

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.